Cardiac myosin inhibitors consistently improve gradients and health status in patients with obstructive hypertrophic cardiomyopathy.
Do cardiac myosin inhibitors improve gradients and health status in patients with obstructive hypertrophic cardiomyopathy?
Cardiac myosin inhibitors represent a mechanism-based paradigm for treating obstructive hypertrophic cardiomyopathy, though their ultimate impact relies on long-term outcomes and real-world implementation.
Absolute Event Rate: 0% vs 0%
CMIs establish a mechanism-based paradigm in obstructive HCM with consistent improvements in gradients and health status in randomized trials. Their future impact will depend on long-term outcomes, real-world implementation (monitoring, interactions, access), and identifying nonobstructive phenotypes most likely to benefit.
Shah et al. (Mon,) reported a other. Cardiac myosin inhibitors consistently improve gradients and health status in patients with obstructive hypertrophic cardiomyopathy.